- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
Publication
Article
Dermatology Times
Dr. Reddy’s sells Cloderm to EPI Health
Author(s):
EPI Health has acquired Cloderm Cream (clocortolone pivalate 0.1 percent) and its authorized generic from manufacturer Dr. Reddy’s Laboratories.
Promius Pharma, Dr. Reddy’s wholly owned subsidiary, sold rights to Cloderm in October. Promius Pharma will be entitled to receive an upfront payment and subsequent future royalties, effective immediately. Financial details of the acquisition were not disclosed.
Cloderm is used for the treatment of various skin conditions such as eczema, psoriasis and allergic reactions.
“The addition of this product to our growing portfolio will support our ongoing efforts to build a successful prescription-branded franchise in the United States,” said Ron Owens, EPI Health president.
